Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: Report of 3 fatal cases

American Journal of Surgical Pathology

Volumn 39, Issue 2, 2015, Pages 212-220

  Evans, Ashley T ^a   Loeb, Keith R ^b,d   Shulman, Howard M ^b,d   Hassan, Sajida ^d   Qiu, Wan Chong ^c   Hockenbery, David M ^a,d   Ioannou, George N ^a,e   Chauncey, Thomas R ^a,e   Gretch, David R ^c   McDonald, George B ^a,d  

^a Departments of Psychiatry and Medicine   (United States)

^b Department of Pathology ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

fibrosing cholestatic hepatitis hematopoietic cell transplantation; hepatitis C virus; in situ hybridization; liver disease; mycophenolate mofetil

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ANALOGS AND DERIVATIVES; CASE REPORT; CHOLESTASIS; FATALITY; FIBROSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LEUKEMIA; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; CHOLESTASIS; FATAL OUTCOME; FIBROSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 84922056472     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000345     Document Type: Article

References (38)

1. Shuhart MC, Myerson D, Childs B, et al. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood. 1994;84:3229-3235.
2. Shuhart MC, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection in bone marrow transplant patients after transfusions from anti-HCV positive donors. Bone Marrow Transplant. 1996;17: 601-606.
3. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
4. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology. 1999;29:1893-1899.
5. Peffault de Latour R, Ribaud P, Robin M, et al. Allogeneic hematopoietic cell transplant in HCV-infected patients. J Hepatol. 2008;48:1008-1017.
6. Ramos CA, Saliba RM, de Padua L, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009;94:249-257.
7. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363:2091-2101.
8. Socie G, de Latour RP, McDonald GB. Hepatitis C virus and allogeneic stem cell transplantation still matters! Haematologica. 2009;94:170-172.
9. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood. 1999;93:3259-3266.
10. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl. 2007;13:219-226.
11. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13:150-157.
12. Cooksley WG, McIvor CA. Fibrosing cholestatic hepatitis and HBV after bone marrow transplantation. Biomed Pharmacother. 1995;49: 117-124.
13. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51:1450-1460.
14. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977-1983.
15. Chang M, Marquardt AP, Wood BL, et al. In situ distribution of hepatitis C virus replicative-intermediate RNA in hepatic tissue and its correlation with liver disease. J Virol. 2000;74:944-955.
16. Pal S, Sullivan DG, Kim S, et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology. 2006;130:1107-1116.
17. Lau JY, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology. 1992;102:956-962.
18. Dickson RC, Caldwell SH, Ishitani MB, et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation. 1996; 61:701-705.
19. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815-820.
20. Ceballos-Viro J, Lopez-Picazo JM, Perez-Gracia JL, et al. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. World J Gastroenterol. 2009;15:2290-2292.
21. Delladetsima JK, Boletis JN, Makris F, et al. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg. 1999;5:294-300.
22. Satapathy SK, Sclair S, Fiel MI, et al. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res. 2011;41:328-339.
23. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
24. Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3-26.
25. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996;61:1029-1037.
26. Sarmiento JM, Dockrell DH, Schwab TR, et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant. 2000;14:136-138.
27. Kobashigawa J, Miller L, Renlund D, et al. A randomized activecontrolled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507-515.
28. Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation. 2008;86:1474-1478.
29. Kornberg A, Kupper B, Tannapfel A, et al. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol. 2005;5:107-115.
30. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012;19: 324-335.
31. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004; 104:961-968.
32. Clave E, Busson M, Douay C, et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood. 2009;113: 6477-6484.
33. Lau GK, He M-L, Fong DYT, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702-709.
34. Vance EA, Soiffer RJ, McDonald GB, et al. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation. 1996; 62:1358-1360.
35. Surapaneni SN, Hari P, Knox J, et al. Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. Am J Gastroenterol. 2007;102:449-451.
36. Salomao M, Verna EC, Lefkowitch JH, et al. Histopathologic distinction between fibrosing cholestatic hepatitis C and biliary obstruction. Am J Surg Pathol. 2013;37:1837-1844.
37. Murakami CS, Louie W, Chan GS, et al. Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes. Bone Marrow Transplant. 1999;23:921-927.
38. Strasser SI, Shulman HM, McDonald GB. Cholestasis after hematopoietic cell transplantation. Clin Liver Dis. 1999;3:651-668.